Liu Q
Clin Exp Med. 2025; 25(1):77.
PMID: 40063304
PMC: 11893680.
DOI: 10.1007/s10238-025-01618-x.
Argoetti A, Shalev D, Polyak G, Shima N, Biran H, Lahav T
Nat Commun. 2025; 16(1):571.
PMID: 39794357
PMC: 11723954.
DOI: 10.1038/s41467-025-55822-0.
Podemska E, Borowczak J, Lukasik D, Grzanka D, Durslewicz J
Cancers (Basel). 2024; 16(23).
PMID: 39682098
PMC: 11640366.
DOI: 10.3390/cancers16233909.
Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A
Heliyon. 2024; 10(15):e35208.
PMID: 39170516
PMC: 11337742.
DOI: 10.1016/j.heliyon.2024.e35208.
Chen J, Sun S, Li H, Cai X, Wan C
Front Immunol. 2024; 15:1373321.
PMID: 38596684
PMC: 11003268.
DOI: 10.3389/fimmu.2024.1373321.
Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism.
Yue B, Chen J, Bao T, Zhang Y, Yang L, Zhang Z
Gastric Cancer. 2024; 27(2):308-323.
PMID: 38270815
DOI: 10.1007/s10120-023-01464-4.
The regulatory relationship between transcription factor STAT3 and noncoding RNA.
Liu S, Li W, Liang L, Zhou Y, Li Y
Cell Mol Biol Lett. 2024; 29(1):4.
PMID: 38172648
PMC: 10763091.
DOI: 10.1186/s11658-023-00521-1.
Tumor Suppressor LncRNA on Chromosome 8p12 (TSLNC8): A Concise Review in Human Malignancies.
Li X, Huang H, Liu M, Luo H
J Cancer. 2023; 14(15):2867-2877.
PMID: 37781073
PMC: 10539563.
DOI: 10.7150/jca.87801.
Identification of N7-methylguanosine-related lncRNAs for the risk stratification of hepatocellular carcinoma.
Li Y, Zhao K, Wu R, Wang J, Wang Q, Xiong Q
J Gastrointest Oncol. 2023; 14(3):1392-1411.
PMID: 37435203
PMC: 10331757.
DOI: 10.21037/jgo-23-227.
Advances in Osteosarcoma.
Panez-Toro I, Munoz-Garcia J, Vargas-Franco J, Renodon-Corniere A, Heymann M, Lezot F
Curr Osteoporos Rep. 2023; 21(4):330-343.
PMID: 37329384
PMC: 10393907.
DOI: 10.1007/s11914-023-00803-9.
GABPB1-AS1 acts as a tumor suppressor and inhibits non-small cell lung cancer progression by targeting miRNA-566/F-box protein 47.
Lv H, Lai C, Zhao W, Song Y
Oncol Res. 2023; 29(6):401-409.
PMID: 37304650
PMC: 10207974.
DOI: 10.32604/or.2022.025262.
LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway.
Chen W, Bai Z, Bai W, Wang W, Guo J, Guo M
Sci Rep. 2023; 13(1):7500.
PMID: 37160972
PMC: 10170139.
DOI: 10.1038/s41598-023-33976-5.
LncRNA CASC19: a novel oncogene involved in human cancer.
Wang S, Qiao C, Fang R, Yang S, Zhao G, Liu S
Clin Transl Oncol. 2023; 25(10):2841-2851.
PMID: 37029242
DOI: 10.1007/s12094-023-03165-x.
LncGMDS-AS1 promotes the tumorigenesis of colorectal cancer through HuR-STAT3/Wnt axis.
Ye D, Liu H, Zhao G, Chen A, Jiang Y, Hu Y
Cell Death Dis. 2023; 14(2):165.
PMID: 36849492
PMC: 9970971.
DOI: 10.1038/s41419-023-05700-8.
Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review).
Chen Y, Hsieh C, Chu P, Chen J, Huang Y, Chen C
Oncol Rep. 2023; 49(3).
PMID: 36660927
PMC: 9887465.
DOI: 10.3892/or.2023.8485.
The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma.
Hong Y, Zhang Y, Zhao H, Chen H, Yu Q, Cui H
Front Cell Dev Biol. 2022; 10:1051306.
PMID: 36467404
PMC: 9716033.
DOI: 10.3389/fcell.2022.1051306.
The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth.
Liu G, Yang Z, Sun J, Sun B, Zhou P, Zhou C
Cell Oncol (Dordr). 2022; 45(6):1435-1449.
PMID: 36435866
PMC: 9747837.
DOI: 10.1007/s13402-022-00730-4.
A novel classification of HCC basing on fatty-acid-associated lncRNA.
Xu Y, Yu X, Zhang Q, He Y, Guo W
Sci Rep. 2022; 12(1):18863.
PMID: 36344648
PMC: 9640627.
DOI: 10.1038/s41598-022-23681-0.
LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2 breast cancer.
Bai W, Peng H, Zhang J, Zhao Y, Li Z, Feng X
NPJ Breast Cancer. 2022; 8(1):115.
PMID: 36309503
PMC: 9617889.
DOI: 10.1038/s41523-022-00484-0.
Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors.
Hu X, Wang Z, Su P, Zhang Q, Kou Y
Front Oncol. 2022; 12:933248.
PMID: 36147927
PMC: 9485670.
DOI: 10.3389/fonc.2022.933248.
